Disitamab Vedotin has been granted breakthrough designations in the United States and China, new drug application (NDA) of urothelial carcinoma was accepted
2021-07-15
The first time in China! Two indications of Disitamab Vedotin have been granted breakthrough designations in the United States and China for three times
2021-06-30
Disitamab Vedotin has become the first ADC drug created and developed by a China biopharma to receive marketing approval!
